Moderna Inc - Company Profile
Powered by 
All the data and insights you need on Moderna Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Moderna Inc Strategy Report
- Understand Moderna Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View moreModerna Inc (Moderna) is a biotechnology company that focuses on the development of messenger RNA (mRNA) therapeutics and vaccines. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
325 Binney Street, Cambridge, Massachusetts, 02142
Website
www.modernatx.com
Telephone
1 617 7146500
No of Employees
5,600
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MRNA (NASD)
Revenue (2022)
$6.8B
-64.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-156.4%
(2022 vs 2021)
Market Cap*
$40.3B
Net Profit Margin (2022)
XYZ
-258.6%
(2022 vs 2021)
* As of and is in US$
Moderna Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Spikevax |
| mRNA-1273/Spikevax : COVID-19 vaccine | |
| mRNA-1273.351 : COVID-19 vaccine Beta variant | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Financing Agreements | In March, the company secured US$750 million from Blackstone Life Sciences to advance its flu program. |
| 2024 | Contracts/Agreements | In February, Moderna Canada and the Canadian Alliance for Skills and Training in Life Sciences entered into a partnership to provide support for biomanufacturing training to the employees of Moderna's vaccine manufacturing facility in Laval, Quebec, Canada. |
| 2023 | New Products/Services | In November, the company launched mRNA platform incubator network. |
Competitor Comparison
| Key Parameters | Moderna Inc | Johnson & Johnson | Pfizer Inc | Sanofi | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | France | United Kingdom |
| City | Cambridge | New Brunswick | New York | Paris | Cambridge |
| State/Province | Massachusetts | New Jersey | New York | Ile-de-France | England |
| No. of Employees | 5,600 | 131,900 | 88,000 | 87,994 | 89,900 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Stephane Bancel | Chief Executive Officer; Director | Executive Board | 2011 | 50 |
| James Mock | Chief Financial Officer | Senior Management | 2022 | 46 |
| Brad Miller | Chief Information Officer | Senior Management | 2023 | 50 |
| Shannon Thyme Klinger | Secretary; Chief Legal Officer | Senior Management | 2021 | 51 |
| Kate Cronin | Chief Brand Officer | Senior Management | 2021 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward